The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%

C. Oddoux, J. P. Struewing, C. M. Clayton, S. Neuhausen, L. C. Brody, M. Kaback, B. Haas, L. Norton, P. Borgen, S. Jhanwar, D. Goldgar, Harry Ostrer, K. Offit

Research output: Contribution to journalArticle

306 Citations (Scopus)

Abstract

Certain germline mutations in either BRCA1 or BRCA2 confer a lifetime risk of developing breast cancer that may approach 90%. The BRCA1 185delAG mutation was found in 20% and the BRCA2 6174delT mutation in 8% of Ashkenazi Jewish women with early-onset breast cancer. The 185delAG mutation was observed in 0.9% of 858 Ashkenazi Jews unselected for a personal or family history of cancer. Assuming comparable age-specific penetrances, a carrier frequency of 0.3% was estimated for the 6174delT BRCA2 mutation. To test this hypothesis, we performed a population survey of 1,255 Jewish individuals. In two independent groups, a prevalence of approximately 1% (C.I. 0.6-1.5) was observed for the 6174delT mutation. The relative risk of developing breast cancer by age 42 was estimated to be 9.3 (C.I. 2.5-22.5) for 6174delT, compared to 31 (C.I. 11-77) for 185delAG. Analysis of 107 Ashkenazi Jewish women with breast cancer and a family history of breast or ovarian cancer confirmed a four-fold greater prevalence for the BRCA1 185delAG mutation compared to the BRCA2 6174delT mutation. Our findings suggest a difference in cumulative lifetime penetrance for the two mutations. Genetic counseling for the one in 50 Ashkenazi Jewish individuals harbouring specific germline mutations in BRCA1 or BRCA2 must be tailored to reflect the different risks associated with the two mutations.

Original languageEnglish (US)
Pages (from-to)188-190
Number of pages3
JournalNature Genetics
Volume14
Issue number2
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Mutation
Breast Neoplasms
Penetrance
Germ-Line Mutation
Jews
Genetic Counseling
Ovarian Neoplasms
Population
Neoplasms

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Oddoux, C., Struewing, J. P., Clayton, C. M., Neuhausen, S., Brody, L. C., Kaback, M., ... Offit, K. (1996). The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nature Genetics, 14(2), 188-190. https://doi.org/10.1038/ng1096-188

The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. / Oddoux, C.; Struewing, J. P.; Clayton, C. M.; Neuhausen, S.; Brody, L. C.; Kaback, M.; Haas, B.; Norton, L.; Borgen, P.; Jhanwar, S.; Goldgar, D.; Ostrer, Harry; Offit, K.

In: Nature Genetics, Vol. 14, No. 2, 1996, p. 188-190.

Research output: Contribution to journalArticle

Oddoux, C, Struewing, JP, Clayton, CM, Neuhausen, S, Brody, LC, Kaback, M, Haas, B, Norton, L, Borgen, P, Jhanwar, S, Goldgar, D, Ostrer, H & Offit, K 1996, 'The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%', Nature Genetics, vol. 14, no. 2, pp. 188-190. https://doi.org/10.1038/ng1096-188
Oddoux, C. ; Struewing, J. P. ; Clayton, C. M. ; Neuhausen, S. ; Brody, L. C. ; Kaback, M. ; Haas, B. ; Norton, L. ; Borgen, P. ; Jhanwar, S. ; Goldgar, D. ; Ostrer, Harry ; Offit, K. / The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. In: Nature Genetics. 1996 ; Vol. 14, No. 2. pp. 188-190.
@article{5d395195fdbe4838a385da2a6948ca18,
title = "The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1{\%}",
abstract = "Certain germline mutations in either BRCA1 or BRCA2 confer a lifetime risk of developing breast cancer that may approach 90{\%}. The BRCA1 185delAG mutation was found in 20{\%} and the BRCA2 6174delT mutation in 8{\%} of Ashkenazi Jewish women with early-onset breast cancer. The 185delAG mutation was observed in 0.9{\%} of 858 Ashkenazi Jews unselected for a personal or family history of cancer. Assuming comparable age-specific penetrances, a carrier frequency of 0.3{\%} was estimated for the 6174delT BRCA2 mutation. To test this hypothesis, we performed a population survey of 1,255 Jewish individuals. In two independent groups, a prevalence of approximately 1{\%} (C.I. 0.6-1.5) was observed for the 6174delT mutation. The relative risk of developing breast cancer by age 42 was estimated to be 9.3 (C.I. 2.5-22.5) for 6174delT, compared to 31 (C.I. 11-77) for 185delAG. Analysis of 107 Ashkenazi Jewish women with breast cancer and a family history of breast or ovarian cancer confirmed a four-fold greater prevalence for the BRCA1 185delAG mutation compared to the BRCA2 6174delT mutation. Our findings suggest a difference in cumulative lifetime penetrance for the two mutations. Genetic counseling for the one in 50 Ashkenazi Jewish individuals harbouring specific germline mutations in BRCA1 or BRCA2 must be tailored to reflect the different risks associated with the two mutations.",
author = "C. Oddoux and Struewing, {J. P.} and Clayton, {C. M.} and S. Neuhausen and Brody, {L. C.} and M. Kaback and B. Haas and L. Norton and P. Borgen and S. Jhanwar and D. Goldgar and Harry Ostrer and K. Offit",
year = "1996",
doi = "10.1038/ng1096-188",
language = "English (US)",
volume = "14",
pages = "188--190",
journal = "Nature Genetics",
issn = "1061-4036",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%

AU - Oddoux, C.

AU - Struewing, J. P.

AU - Clayton, C. M.

AU - Neuhausen, S.

AU - Brody, L. C.

AU - Kaback, M.

AU - Haas, B.

AU - Norton, L.

AU - Borgen, P.

AU - Jhanwar, S.

AU - Goldgar, D.

AU - Ostrer, Harry

AU - Offit, K.

PY - 1996

Y1 - 1996

N2 - Certain germline mutations in either BRCA1 or BRCA2 confer a lifetime risk of developing breast cancer that may approach 90%. The BRCA1 185delAG mutation was found in 20% and the BRCA2 6174delT mutation in 8% of Ashkenazi Jewish women with early-onset breast cancer. The 185delAG mutation was observed in 0.9% of 858 Ashkenazi Jews unselected for a personal or family history of cancer. Assuming comparable age-specific penetrances, a carrier frequency of 0.3% was estimated for the 6174delT BRCA2 mutation. To test this hypothesis, we performed a population survey of 1,255 Jewish individuals. In two independent groups, a prevalence of approximately 1% (C.I. 0.6-1.5) was observed for the 6174delT mutation. The relative risk of developing breast cancer by age 42 was estimated to be 9.3 (C.I. 2.5-22.5) for 6174delT, compared to 31 (C.I. 11-77) for 185delAG. Analysis of 107 Ashkenazi Jewish women with breast cancer and a family history of breast or ovarian cancer confirmed a four-fold greater prevalence for the BRCA1 185delAG mutation compared to the BRCA2 6174delT mutation. Our findings suggest a difference in cumulative lifetime penetrance for the two mutations. Genetic counseling for the one in 50 Ashkenazi Jewish individuals harbouring specific germline mutations in BRCA1 or BRCA2 must be tailored to reflect the different risks associated with the two mutations.

AB - Certain germline mutations in either BRCA1 or BRCA2 confer a lifetime risk of developing breast cancer that may approach 90%. The BRCA1 185delAG mutation was found in 20% and the BRCA2 6174delT mutation in 8% of Ashkenazi Jewish women with early-onset breast cancer. The 185delAG mutation was observed in 0.9% of 858 Ashkenazi Jews unselected for a personal or family history of cancer. Assuming comparable age-specific penetrances, a carrier frequency of 0.3% was estimated for the 6174delT BRCA2 mutation. To test this hypothesis, we performed a population survey of 1,255 Jewish individuals. In two independent groups, a prevalence of approximately 1% (C.I. 0.6-1.5) was observed for the 6174delT mutation. The relative risk of developing breast cancer by age 42 was estimated to be 9.3 (C.I. 2.5-22.5) for 6174delT, compared to 31 (C.I. 11-77) for 185delAG. Analysis of 107 Ashkenazi Jewish women with breast cancer and a family history of breast or ovarian cancer confirmed a four-fold greater prevalence for the BRCA1 185delAG mutation compared to the BRCA2 6174delT mutation. Our findings suggest a difference in cumulative lifetime penetrance for the two mutations. Genetic counseling for the one in 50 Ashkenazi Jewish individuals harbouring specific germline mutations in BRCA1 or BRCA2 must be tailored to reflect the different risks associated with the two mutations.

UR - http://www.scopus.com/inward/record.url?scp=16044366988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16044366988&partnerID=8YFLogxK

U2 - 10.1038/ng1096-188

DO - 10.1038/ng1096-188

M3 - Article

VL - 14

SP - 188

EP - 190

JO - Nature Genetics

JF - Nature Genetics

SN - 1061-4036

IS - 2

ER -